In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer.

Key topics included:

• The definition and characteristics of high-risk non-muscle invasive bladder cancer.
• Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment.
• The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach.
• Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy.

Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

• ⁠X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer